Weight-loss jabs could be sold for as little as £20 a month as more drugmakers may soon be free to produce cut-price alternatives to the medications, a trade body has suggested.
Firm Novo Nordisk’s global patent is set to expire in parts of the world from early 2026, allowing cut-price “generic” versions of Wegovy and Ozempic to be sold by other companies, according to reports.
